NT5E and neoplasm: Consistent with the worse prognosis observed in patients bearing tumor with high intratumoral CD73 expression assessed by immunohistochemistry [8, 28–31], patients with rad-CD73High CRLM had a shorter median TTR of 13.0 months compared to 23.6 months in rad-CD73Low CRLM patients (P = 0.0098).